Fresenius: Receives FDA Approval For Denosumab Biosimilars And Secures Global Settlement
Reuters
27 Mar
March 26 (Reuters) - FRESENIUS SE & CO KGAA :: *FRESENIUS SE - RECEIVES FDA APPROVAL FOR THEIR DENOSUMAB BIOSIMILARS AND SECURES GLOBAL SETTLEMENT *FRESENIUS SE - DENOSUMAB BIOSIMILARS ARE APPROVED FOR ALL INDICATIONS OF THE REFERENCE PRODUCTS PROLIA®* (DENOSUMAB) AND XGEVA®* (DENOSUMAB), RESPECTIVELY *FRESENIUS SE - FRESENIUS’ OPERATING COMPANY REACHED GLOBAL SETTLEMENT WITH AMGEN, ALLOWING LAUNCH OF THESE BIOSIMILARS IN THE US FROM MID-2025 AND IN EUROPE LATER IN H2 OF 2025 *Further company coverage: FREG.DE * (Gdansk Newsroom) * ((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.